60 mg QD Alogabat ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 201 | Angelman syndrome | 1 |
201. Angelman syndrome
Clinical trials : 25 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 22 - Drug target pathways : 20
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05630066 (ClinicalTrials.gov) | June 1, 2023 | 9/11/2022 | Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype | A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype | Angelman Syndrome | Drug: 60 mg QD Alogabat;Drug: 40 mg QD Alogabat;Drug: 7 mg QD Alogabat;Drug: Part 2 Adult Alogabat High Dose (aged 15-17);Drug: Alogabat | Hoffmann-La Roche | NULL | Not yet recruiting | 5 Years | 17 Years | All | 56 | Phase 2 | NULL |